Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Family Medicine
Disease Category: Solid Tumors
Location: United States, CA
An Open-Label Phase I Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects with Cancer Who Also Have Impaired Renal Function
The purposes of this study are:
- Primary - To determine the effect of kidney damage on the amount of Halaven™ in your blood and how quickly the body gets rid of it
- Secondary - To explore the safety of Halaven™ in subjects with kidney damage
- Exploratory - To see if Halaven™ causes any decrease in the size of your cancer.
You have been asked to join this study because your doctor or the study doctor has found that you have advanced cancer, which has not responded or worsened after you were treated with approved therapies. You also have kidney disease or damage, which may be preventing you from receiving treatments that are currently available and may have an effect on your body’s ability to process and get rid of medications you are taking.
Patient Inclusion/Exclusion Criteria:
- See http://clinicaltrials.coh.org for additional information.
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)
Research Center Information: City of Hope
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these